Medicus Pharma Ltd. Common Stock (MDCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medicus Pharma Ltd. Common Stock (MDCX) has a cash flow conversion efficiency ratio of 4.078x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.96 Million) by net assets ($-1.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Medicus Pharma Ltd. Common Stock market capitalisation for the company's overall valuation and market capitalisation.
Medicus Pharma Ltd. Common Stock - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Medicus Pharma Ltd. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medicus Pharma Ltd. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicus Pharma Ltd. Common Stock ranked by their cash flow conversion efficiency. See how well can Medicus Pharma Ltd. Common Stock service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dfcity Group Bhd
KLSE:5165
|
0.025x |
|
ECOUP OYJ EO 1
F:62H
|
N/A |
|
Skyline Investment S.A.
WAR:SKL
|
-0.002x |
|
Dataworks Group Ltd
AU:DWG
|
-0.337x |
|
The House of Agriculture Spiroy S.A.
AT:SPIR
|
0.757x |
|
Godolphin Resources Ltd
AU:GRL
|
-0.172x |
|
Solartron Public Company Limited
BK:SOLAR
|
-0.010x |
|
REC Silicon ASA
OL:RECSI
|
0.174x |
Annual Cash Flow Conversion Efficiency for Medicus Pharma Ltd. Common Stock (2010–2025)
The table below shows the annual cash flow conversion efficiency of Medicus Pharma Ltd. Common Stock from 2010 to 2025. View MDCX stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $37.31K | $-22.78 Million | -610.457x | -18574.34% |
| 2024-12-31 | $3.13 Million | $-10.25 Million | -3.269x | +12.63% |
| 2023-12-31 | $1.11 Million | $-4.16 Million | -3.741x | -4417.13% |
| 2022-12-31 | $-12.20 Million | $-1.06 Million | 0.087x | -37.13% |
| 2021-12-31 | $-10.51 Million | $-1.45 Million | 0.138x | -86.91% |
| 2017-12-31 | $-62.65K | $-65.99K | 1.053x | +75.08% |
| 2010-12-31 | $-2.00 Million | $-1.20 Million | 0.602x | -- |
About Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The com… Read more